Recommended Phase 2 Dose of Tebentafusp Shows Promise in Metastatic Uveal Melanoma

Source: Targeted Oncology, June 2022

A manageable side-effect profile, signal of efficacy, and 36% increase in the recommended phase 2 dose (RP2D) was seen with a step-up dosing regimen of tebentafusp in patients with metastatic uveal melanoma.

A step-up dosing regimen of tebentafusp (IMCgp100) showed a manageable side-effect profile, a signal of efficacy, and led to a 36% increase in the recommended phase 2 dose (RP2D) compared with weekly fixed dosing in patients with metastatic uveal melanoma (mUM), according to data from the phase 1/2 study (NCT02570308) published in the Journal of Clinical Oncology.

This open-label, international, phase 1 study examined the RP2D of the first-in-class T-cell receptor/anti-CD3 bispecific protein, tebentafusp, in patients with mUM. Investigators used a 3-week step-up dosing regimen in order to evaluate the safety, pharmacokinetics, pharmacodynamics, and preliminary clinical activity of tebentafusp in this patient population.

READ THE ORIGINAL FULL ARTICLE